About danicopan
Complement factor D inhibitor
Used for
- Add-on treatment for adults with paroxysmal nocturnal haemoglobinuria who have persistent haemolysis despite ravulizumab or eculizumab.
Usual adult dose
150 mg by mouth three times daily, alongside ravulizumab or eculizumab; may be increased to 200 mg three times daily if needed.
Common side effects
- Headache
- Nausea
- Joint pain
- Increased liver enzymes
Important warnings
- Serious meningococcal and other encapsulated bacterial infections can occur; vaccination is required.
- Do not stop suddenly without medical supervision; haemolysis may worsen.
- Monitor liver enzymes before treatment and during therapy.
- Use only with ravulizumab or eculizumab for this indication.
Pregnancy
Human pregnancy data are limited; use only if potential benefit justifies possible fetal risk.
Breastfeeding
It is unknown whether danicopan passes into breast milk; effects on a nursing infant are unknown.
Interactions
- Strong CYP3A4 inhibitors can increase danicopan exposure.
- Strong CYP3A4 inducers can reduce danicopan exposure.
- Danicopan may affect medicines metabolised by CYP3A4, CYP2C8, or CYP2C9.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.